Precision BioSciences, Inc.

Some of the best links we picked up around the internet

CMN Weekly (21 March 2025) - Your Weekly CRISPR...

CMN Weekly

Mar. 21, 2025

Some of the best links we picked up around the internet

FDA Clears First-Ever In Vivo Gene-Editing Trial...

CMN Clinical

Mar. 19, 2025

Durham-based Precision BioSciences has received IND clearance for PBGENE-HBV, making it the first investigational in vivo gene-editing therapy to...

CMN Weekly (28 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 28, 2025

Some of the best links we picked up around the internet

The Latest Updates From the Gene-Editing Clinical...

CMN Clinical

Feb. 26, 2025

YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

CMN Weekly (20 December 2024) - Your Weekly CRISPR...

CMN Weekly

Dec. 20, 2024

Some of the best links we picked up around the internet

CMN Weekly (15 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 15, 2024

Some of the best links we picked up around the internet

Precision BioSciences, Inc.

Chronic Hepatitis B, HBV, (NCT06680232)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study (NCT05822427)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

B-Cell Non-Hodgkin Lymphoma, NHL, (NCT04649112)
Sponsors:
Precision BioSciences Inc.

IND Enabling

Phase I

Phase II

Phase III

B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT03666000)
Sponsors:
Imugene Limited

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Lymphoma and Leukaemia, (NCT04030195)
Sponsors:
Precision BioSciences, Inc.

IND Enabling

Phase I

Phase II

Phase III